SPOBAG AG (SBE) - Total Assets
Based on the latest financial reports, SPOBAG AG (SBE) holds total assets worth €137.67K EUR (≈ $160.96K USD) as of December 2024. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See SBE total equity for net asset value and shareholders' equity analysis.
SPOBAG AG - Total Assets Trend (2016–2024)
This chart illustrates how SPOBAG AG's total assets have evolved over time, based on quarterly financial data.
SPOBAG AG - Asset Composition Analysis
Current Asset Composition (December 2024)
SPOBAG AG's total assets of €137.67K consist of 0.0% current assets and 100.0% non-current assets.
| Asset Category | Amount (EUR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 0.0% |
| Accounts Receivable | €0.00 | 0.0% |
| Inventory | €0.00 | 0.0% |
| Property, Plant & Equipment | €0.00 | 0.0% |
| Intangible Assets | €0.00 | 0.0% |
| Goodwill | €0.00 | 0.0% |
Asset Composition Trend (2016–2024)
This chart illustrates how SPOBAG AG's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see market value of SPOBAG AG.
Key Asset Composition Facts
- Current vs. Non-Current Assets: SPOBAG AG's current assets represent 0.0% of total assets in 2024, a decrease from 99.2% in 2016.
- Cash Position: Cash and equivalents constituted 0.0% of total assets in 2024, down from 96.7% in 2016.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2016.
- Asset Diversification: The largest asset category is goodwill at 0.0% of total assets.
SPOBAG AG Competitors by Total Assets
Key competitors of SPOBAG AG based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
| No similar companies found. | ||
SPOBAG AG - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.00 | 0.14 | 4.20 |
| Quick Ratio | 0.00 | 0.14 | 4.20 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | €-31.13K | €-32.93K | €4.80K |
SPOBAG AG - Advanced Valuation Insights
This section examines the relationship between SPOBAG AG's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.18 |
| Latest Market Cap to Assets Ratio | 25.42 |
| Asset Growth Rate (YoY) | 46.5% |
| Total Assets | €137.67K |
| Market Capitalization | $3.50 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values SPOBAG AG's assets at a significant premium (25.42x), suggesting investors see substantial growth potential or unique competitive advantages.
Rapid Asset Growth: SPOBAG AG's assets grew by 46.5% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for SPOBAG AG (2016–2024)
The table below shows the annual total assets of SPOBAG AG from 2016 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | €137.67K ≈ $160.96K |
+46.52% |
| 2023-12-31 | €93.97K ≈ $109.86K |
-69.03% |
| 2022-12-31 | €303.38K ≈ $354.68K |
+30.51% |
| 2021-12-31 | €232.46K ≈ $271.77K |
+27.48% |
| 2020-12-31 | €182.35K ≈ $213.18K |
+47.91% |
| 2019-12-31 | €123.28K ≈ $144.13K |
+52.05% |
| 2018-12-31 | €81.08K ≈ $94.79K |
+64.68% |
| 2017-12-31 | €49.23K ≈ $57.56K |
-37.63% |
| 2016-12-31 | €78.93K ≈ $92.28K |
-- |
About SPOBAG AG
Leo International Precision Health AG engages in the healthcare technology business in Germany. The company is based in Garching bei München, Germany.